ESR1 and hepatocellular carcinoma: This would imply that immunocytochemically ER-negative HCC could yet express ERα36, indicating that routine evaluation of ER status based solely on immunohistochemistry could often be inadequate for a comprehensive assessment of ER status and estrogen signaling in liver tissues and cells and, therefore, could fail to provide potentially important information on ‘‘ER-negative’’ HCC patients.